Processing

Please wait...

Settings

Settings

Goto Application

1. WO2007141005 - USE OF GLUTAMYL AMINOPEPTIDASE (ENPEP) AS A THERAPEUTIC OR DIAGNOSTIC TARGET

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

Claims

1. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer in a mammal comprising the steps of

- contacting a test compound with a ENEP polypeptide,

detect binding of said test compound to said ENEP polypeptide.

2. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer in a mammal comprising the steps of

- determining the activity of a ENEP polypeptide at a certain concentration of a test compound or in the absence of said test compound,

determining the activity of said polypeptide at a different concentration of said test compound.

3. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer in a mammal comprising the steps of

determining the activity of a ENEP polypeptide at a certain concentration of a test compound,

determining the activity of a ENEP polypeptide at the presence of a compound known to be a regulator of a ENEP polypeptide.

4. The method of any of claims 1 to 3, wherein the step of contacting is in or at the surface of a cell.

5. The method of any of claims 1 to 3, wherein the cell is in vitro.

6. The method of any of claims 1 to 3, wherein the step of contacting is in a cell-free system.

7. The method of any of claims 1 to 3, wherein the polypeptide is coupled to a detectable label.

8. The method of any of claims 1 to 3, wherein the compound is coupled to a detectable label.

9. The method of any of claims 1 to 3, wherein the test compound displaces a ligand which is first bound to the polypeptide.

10. The method of any of claims 1 to 3, wherein the polypeptide is attached to a solid support.

11. The method of any of claims 1 to 3, wherein the compound is attached to a solid support.

12. A method of screening for therapeutic agents useful in the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer in a mammal comprising the steps of

contacting a test compound with a ENEP polynucleotide,

detect binding of said test compound to said ENEP polynucleotide.

13. The method of claim 12 wherein the nucleic acid molecule is RNA.

14. The method of claim 12 wherein the contacting step is in or at the surface of a cell.

15. The method of claim 12 wherein the contacting step is in a cell-free system.

16. The method of claim 12 wherein polynucleotide is coupled to a detectable label.

17. The method of claim 12 wherein the test compound is coupled to a detectable label.

18. A method of diagnosing a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer in a mammal comprising the steps of

determining the amount of a ENEP polynucleotide in a sample taken from said mammal,

- determining the amount of ENEP polynucleotide in healthy and/or diseased mammals.

19. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer in a mammal comprising a therapeutic agent which binds to a ENEP polypeptide.

20. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer in a mammal comprising a therapeutic agent which regulates the activity of a ENEP polypeptide.

21. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer in a mammal comprising a therapeutic agent which regulates the activity of a

ENEP polypeptide, wherein said therapeutic agent is

a small molecule,

an RNA molecule,

an antisense oligonucleotide,

- a polypeptide,

an antibody, or

a ribozyme.

22. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer in a mammal comprising a ENEP polynucleotide.

23. A pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer in a mammal comprising a ENEP polypeptide.

24. Use of regulators of a ENEP for the preparation of a pharmaceutical composition for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer in a mammal.

25. Method for the preparation of a pharmaceutical composition useful for the treatment of a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer in a mammal comprising the steps of

identifying a regulator of ENEP, determining whether said regulator ameliorates the symptoms of a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer in a mammal; and

combining of said regulator with an acceptable pharmaceutical carrier.

26. Use of a regulator of ENEP for the regulation of ENEP activity in a mammal having a disease comprised in a group of diseases consisting of cardiovascular diseases, hematological diseases, urological diseases and cancer.